JP2003501385A - Ｈｍｇ−ｃｏａレダクターゼ阻害剤とカルニチン類を含む抗高脂血症性組合せ - Google Patents

Ｈｍｇ−ｃｏａレダクターゼ阻害剤とカルニチン類を含む抗高脂血症性組合せ

Info

Publication number
JP2003501385A
JP2003501385A JP2001501212A JP2001501212A JP2003501385A JP 2003501385 A JP2003501385 A JP 2003501385A JP 2001501212 A JP2001501212 A JP 2001501212A JP 2001501212 A JP2001501212 A JP 2001501212A JP 2003501385 A JP2003501385 A JP 2003501385A
Authority
JP
Japan
Prior art keywords
carnitine
alkanoyl
statin
acid
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001501212A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003501385A5 (https=
Inventor
アルドゥイーノ・アルドゥイーニ
アレッサンドロ・ペスケケラ
パオロ・カルミナティ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP99830415A external-priority patent/EP1064943B1/en
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Publication of JP2003501385A publication Critical patent/JP2003501385A/ja
Publication of JP2003501385A5 publication Critical patent/JP2003501385A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2001501212A 1999-06-08 2000-06-05 Ｈｍｇ−ｃｏａレダクターゼ阻害剤とカルニチン類を含む抗高脂血症性組合せ Pending JP2003501385A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13800899P 1999-06-08 1999-06-08
US60/138,008 1999-06-08
EP99830415.8 1999-06-30
EP99830415A EP1064943B1 (en) 1999-06-30 1999-06-30 Combination having antilipemic activity substantially free from toxic or side effects due to antilipemic drugs
PCT/EP2000/005091 WO2000074675A1 (en) 1999-06-08 2000-06-05 Antilipemic combinations comprising hmg-coa reductase inhibitors and carnitines

Publications (2)

Publication Number Publication Date
JP2003501385A true JP2003501385A (ja) 2003-01-14
JP2003501385A5 JP2003501385A5 (https=) 2007-07-05

Family

ID=26153794

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001501212A Pending JP2003501385A (ja) 1999-06-08 2000-06-05 Ｈｍｇ−ｃｏａレダクターゼ阻害剤とカルニチン類を含む抗高脂血症性組合せ

Country Status (10)

Country Link
JP (1) JP2003501385A (https=)
KR (1) KR100725263B1 (https=)
AU (1) AU782188B2 (https=)
CA (1) CA2375378C (https=)
CZ (1) CZ20014218A3 (https=)
HU (1) HUP0201597A3 (https=)
MX (1) MXPA01012644A (https=)
PL (1) PL197899B1 (https=)
SK (1) SK285900B6 (https=)
WO (1) WO2000074675A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010519333A (ja) * 2007-02-27 2010-06-03 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ ２型糖尿病の処置に有用な組成物
JP2012110714A (ja) * 2010-11-24 2012-06-14 Fujitsu Ltd スタチン誘発性ミオパシー及び他の医的障害のセンサベースの診断

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3369738B1 (en) * 2005-11-18 2020-05-20 Cornell Research Foundation, Inc. Method for making nicotinoyl ribosides and nicotinamide beta-riboside
NZ579767A (en) * 2007-03-21 2012-04-27 Sigma Tau Ind Farmaceuti Acetyl L-carnitine, optionally combined with an antihypertensive drug or a statin, for the prevention of type 2 diabetes and its complications in pre-diabetic patients with insulin resistance
PE20091564A1 (es) * 2008-02-29 2009-11-04 Biolab Sanus Farmaceutica Ltda Composicion farmaceutica de un derivado racetam y carnitina

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62126126A (ja) * 1985-11-28 1987-06-08 Snow Brand Milk Prod Co Ltd 経腸栄養剤
JPH02233611A (ja) * 1989-01-18 1990-09-17 Merck & Co Inc ＨＭＧ―ＣｏＡレダクターゼ阻害剤と併用される補酵素Ｑ↓１↓０
WO1999001126A1 (en) * 1997-07-01 1999-01-14 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Pharmaceutical compositions comprising alkanoyl l-carnitine in combination with a statine for treating pathologies brought about by an altered lipid metabolism

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62126126A (ja) * 1985-11-28 1987-06-08 Snow Brand Milk Prod Co Ltd 経腸栄養剤
JPH02233611A (ja) * 1989-01-18 1990-09-17 Merck & Co Inc ＨＭＧ―ＣｏＡレダクターゼ阻害剤と併用される補酵素Ｑ↓１↓０
WO1999001126A1 (en) * 1997-07-01 1999-01-14 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Pharmaceutical compositions comprising alkanoyl l-carnitine in combination with a statine for treating pathologies brought about by an altered lipid metabolism

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010519333A (ja) * 2007-02-27 2010-06-03 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ ２型糖尿病の処置に有用な組成物
JP2014040442A (ja) * 2007-02-27 2014-03-06 Sigma Tau Ind Farmaceut Riunite Spa ２型糖尿病の処置に有用な組成物
JP2012110714A (ja) * 2010-11-24 2012-06-14 Fujitsu Ltd スタチン誘発性ミオパシー及び他の医的障害のセンサベースの診断

Also Published As

Publication number Publication date
HUP0201597A2 (en) 2002-09-28
PL197899B1 (pl) 2008-05-30
PL352106A1 (en) 2003-07-28
AU782188B2 (en) 2005-07-07
CZ20014218A3 (cs) 2002-04-17
SK17152001A3 (sk) 2002-03-05
WO2000074675A1 (en) 2000-12-14
SK285900B6 (sk) 2007-10-04
KR100725263B1 (ko) 2007-06-07
AU5969700A (en) 2000-12-28
CA2375378C (en) 2009-08-11
KR20020025066A (ko) 2002-04-03
CA2375378A1 (en) 2000-12-14
MXPA01012644A (es) 2002-07-22
HUP0201597A3 (en) 2003-04-28

Similar Documents

Publication Publication Date Title
US8258125B2 (en) HDL-boosting combination therapy complexes
JPH04225916A (ja) 脂血障害の治療用組成物
CA2251972A1 (en) Combination therapy for reducing the risks associated with cardiovascular disease
US6673831B1 (en) Combination therapy for reducing the risks associated with cardiovascular disease
US11911382B2 (en) Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension
AU726822B2 (en) Pharmaceutical compositions comprising alkanoyl L-carnitine in combination with a statine for treating pathologies brought about by an altered lipid metabolism
US6245800B1 (en) Method of preventing or treating statin-induced toxic effects using L-carnitine or an alkanoyl L-carnitine
JP2003501385A (ja) Ｈｍｇ−ｃｏａレダクターゼ阻害剤とカルニチン類を含む抗高脂血症性組合せ
JP2006508995A (ja) 血清トリグリセリド値を低下させるためのＰＰＡＲαアゴニスト及びメトホルミンの使用
JP2003503342A (ja) ＭＴＰ阻害剤とＨＭＧ−ＣｏＡ還元酵素阻害剤との組み合わせ並びに薬剤におけるその使用
CN113134086B (zh) 一种降血脂的药物组合物
US20080070938A1 (en) Medicinal composition for mitigating blood lipid or lowering blood homocysteine
JP6227535B2 (ja) 脂質異常症の予防又は治療薬
EP1064943B1 (en) Combination having antilipemic activity substantially free from toxic or side effects due to antilipemic drugs
MXPA99011665A (en) Pharmaceutical compositions comprising alkanoyl l-carnitine in combination with a statine for treating pathologies brought about by an altered lipid metabolism
WO2004082702A1 (en) Use of low molecular weight thrombin inhibitors in cholesterol-lowering therapy
RU2001124663A (ru) Применение средства, снижающего содержание холестерина

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070516

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070516

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100907

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101207

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101214

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110107

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110207

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110329